secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nkarta, Inc. (NKTX)
CIK:        0001787400
Form:       8-K
Filed at:   2024-08-13T23:59:59+00:00
Accession:  0000950170-24-096163
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nkarta Q2 net loss $25M; cash $426.7M; plans Ntrust-2 trial by year-end
-----------------------------------------------------------------------

- Net loss of $25.0M ($0.34 per share) for Q2 2024; R&D expenses $23.1M, G&A $7.6M.
- Cash, equivalents and investments of $426.7M at June 30, 2024; expected to fund operations into late 2027.
- FDA clearance received for second IND for NKX019 in autoimmune disease; Ntrust-2 enrollment expected by year-end 2024.
- Preliminary data from Ntrust-1 and Ntrust-2 planned for 2025; IST in SLE/LN initiated at Columbia University.
- Nadir Mahmood joined as President; David Shook promoted to CMO, Head of R&D in July 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787400/000095017024096163/0000950170-24-096163-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787400/000095017024096163/nktx-20240813.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-096163

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer